ICD-10 code C07: Malignant neoplasm of parotid gland

Key Takeaways

ICD-10 code C07 is the only billable diagnosis code for malignant neoplasm of parotid gland, valid for FY 2025 and 2026.

C07 has no subcodes; it covers all histological subtypes including adenoid cystic carcinoma and mucoepidermoid carcinoma.

Always use additional codes for lymph node involvement and distant metastasis, and document TNM stage directly in the note when a formal staging workup is completed.

Practice management software like Pabau includes claims management tools that help ENT and oncology practices submit C07 claims with accurate supporting documentation.

ICD-10 code C07 is the billable diagnosis code for malignant neoplasm of the parotid gland, the most common site for salivary gland tumors. It has no subcategories, and every histological subtype maps to this single code.

Claims using C07 still get denied regularly because of missing secondary codes, incomplete staging documentation, and confusion with the benign equivalent D11.0. This guide covers the ICD-10 classification system rules specific to C07, so your team can submit cleaner claims and support accurate oncology records from the first encounter.

Parotid gland malignancies account for the majority of all salivary gland cancers, according to the National Cancer Institute. C07 sits within the C00-C14 range (malignant neoplasms of the lip, oral cavity, and pharynx) under the broader Chapter 2 neoplasm chapter (C00-D49).

Understanding where C07 lives in the hierarchy, what it includes, and which companion codes are required is the foundation of accurate billing for this diagnosis.

ICD-10 code C07: Definition and clinical description

The parotid glands are the largest of the three paired major salivary glands, located anterior to and just below each ear. They produce serous saliva and drain into the oral cavity via Stensen’s duct.

Most salivary gland tumors originate in the parotid glands, making C07 the most frequently used salivary gland malignancy code in oncology billing. Non-neoplastic salivary gland disease (K11.9) produces similar swelling, so pathology confirmation remains essential before assigning C07.

C07 is confirmed as billable and valid for FY 2025 and FY 2026 by both the CMS ICD-10 codes page and the WHO classification hierarchy. There are no subcodes beneath C07. All parotid gland malignancies, regardless of histological subtype, map to this single code.

code hierarchy for C07

Inclusion terms and synonyms

The ICD-10-CM tabular list and the AAPC Codify ICD-10-CM lookup both confirm that C07 includes the following synonyms and inclusion terms:

• Adenoid cystic carcinoma of the parotid gland
• Mucoepidermoid carcinoma of the parotid gland
• Acinic cell carcinoma of the parotid gland
• Carcinoma ex pleomorphic adenoma (parotid)
• Malignant mixed tumor of parotid gland
• Parotid gland cancer (all histological subtypes)

Because C07 captures all histological subtypes at once, coders should not select a more specific code for adenoid cystic carcinoma versus mucoepidermoid carcinoma at the ICD-10-CM diagnosis level. Morphology specificity is handled through separate ICD-O-3 codes used in cancer registry reporting, not in claim submission.

Billable status and coding guidelines for C07

C07 is valid for claim submission as both a principal and a secondary diagnosis code. It requires no additional digit for billability. However, the ICD-10-CM Official Guidelines for Coding and Reporting require coders to use additional codes alongside C07 in many clinical scenarios.

Required and instructional additional codes

Several “Use Additional code” instructions apply to C07. These are not optional. Omitting them is a common reason for claim denial or audit flags. Using claims management software that supports multi-code claim builds can reduce these errors significantly.

For more on documenting these risk factors, see our guides to alcohol use disorder (ICD-10 code F10) and tobacco non-user screening (HCPCS code G9903).

Coders should also document TNM stage (clinical or pathological) directly in the note when the physician completes a formal staging workup. ICD-10-CM has no dedicated staging code range for this. TNM stage is captured for cancer registry reporting through AJCC staging and ICD-O-3 coding, not through the diagnosis code itself.

When the record includes head and neck ICD-10 codes for secondary involvement, sequence them after C07 unless the secondary site is the reason for the encounter.

C07 vs. D11.0: Distinguishing malignant from benign parotid neoplasms

The most consequential coding decision for parotid gland tumors is the malignant-versus-benign distinction. Getting this wrong inverts the clinical picture on the claim and can trigger payer audits or authorization issues.

Before assigning C07, coders need a pathology-confirmed diagnosis of malignancy in the physician’s documentation. Imaging findings alone, such as a CT or MRI showing a parotid mass, are not sufficient to code C07.

If malignancy is suspected but not yet confirmed, use code R22.1 (localized swelling, lump, or mass of neck) or similar signs and symptoms codes until pathology results are available. Accurate related diagnostic code documentation at each encounter stage prevents retrospective coding errors.

Documentation requirements to support ICD-10 code C07

Payers scrutinize head and neck malignancy claims carefully. Missing documentation, more than coding mistakes, drives most C07 denials. The record must establish both the diagnosis and the clinical rationale for every encounter billed under C07.

Minimum required documentation elements

• Pathology report: Confirms malignancy, specifies histological subtype (adenoid cystic, mucoepidermoid, acinic cell, etc.), and identifies laterality (right or left parotid)
• TNM staging: Clinical or pathological staging documented by the treating physician, not just referenced from an external report
• Treatment plan: Surgery type (superficial vs. total parotidectomy), adjuvant radiation such as high dose brachytherapy preparation (CCSD code X6015), systemic therapy, or surveillance plan
• Lymph node status: Documentation of N0 (no regional node involvement) through N3 stages, with pathological confirmation where available
• Tobacco and alcohol history: Explicitly documented if present, to support any additional codes assigned
• Physician signature and date: Every note supporting a malignancy code must include attending or treating physician attestation

Structured clinical documentation also supports DRG assignment accuracy. C07 is grouped under head and neck malignancy DRGs, and the DRG weight — and therefore the reimbursement — varies depending on whether the record supports a major or minor complication/comorbidity (MCC or CC) designation.

Practices using structured clinical documentation tools can ensure these elements are captured consistently at each visit, reducing retrospective queries to physicians.

EHR documentation workflow for ENT and oncology practices

The documentation workflow for a parotid gland malignancy typically spans multiple encounters. Each phase has distinct coding implications that require EHR integration for oncology workflows to capture without manual handoffs.

• Initial presentation: Use symptom codes such as cervical lymphadenopathy (R59.0), facial asymmetry, or facial nerve weakness until pathology is confirmed
• Post-biopsy: Assign C07 once the pathology report from a biopsy or fine needle aspiration (CPT code 10021) is available and documented in the record; add histological detail in the clinical note even though C07 does not subcategorize by subtype
• Surgical encounter: C07 as principal diagnosis for parotidectomy procedures; secondary codes for lymph node dissection if performed, such as CCSD code T8700 for excision biopsy of a lymph node
• Follow-up and surveillance: C07 remains the primary diagnosis code; add Z08 (encounter for follow-up examination after completed treatment for malignant neoplasm) as appropriate, typically billed with an established-patient E/M code such as CPT code 99214
• Recurrence: Re-assign C07 with documentation confirming local recurrence; if previously treated with surgery, the record must distinguish recurrence from residual disease

Related ICD-10 codes and crosswalk for parotid malignancy

ICD-10 code C07 does not exist in isolation. Several adjacent and related codes are routinely used alongside it or in its place depending on clinical circumstances. Knowing these prevents under-coding and avoids upcoding risk.

Adjacent salivary gland malignancy codes

The WHO ICD-10 browser provides hierarchical navigation that helps coders confirm code relationships and exclusion notes before submitting. For parotid gland malignancy, always verify whether the physician has documented the specific gland affected. C08.9 should be a last resort, not a default.

Malignancies at other pharyngeal sites, such as the posterior wall of the nasopharynx (C11.1) or its anterior wall (C11.3), sit within the same C00-C14 block and follow similar staging and documentation rules.

Common C07 coding errors and how to avoid them

Parotid gland malignancy claims fail at a higher rate than many other head and neck oncology codes because the clinical scenarios are complex and span multiple specialties. Three error patterns account for the majority of avoidable denials.

Error 1: Coding C07 before pathology confirmation

C07 requires a confirmed malignancy diagnosis. Coders sometimes assign it based on imaging reports that describe a “suspicious” or “likely malignant” mass without a corresponding pathology result. Payers routinely deny these claims or flag them for post-payment audit. Code the presenting symptom until pathology is back.

Error 2: Missing secondary codes for lymph node metastasis

When the surgeon documents level II-V neck dissection findings and pathology confirms nodal involvement, C77.0 must be added as a secondary code. If the spread crosses multiple nodal groups, C77.8 (secondary cancer, multiple lymph nodes) applies instead.

Submitting only C07 when the record documents nodal disease is under-coding. It understates the clinical picture, reduces DRG weight, and may leave revenue on the table.

Error 3: Using C08.9 instead of C07

Many coders default to C08.9 (major salivary gland, unspecified) when the parotid gland is clearly identified in the record. If the operative report, pathology report, or clinical note names the parotid gland, use C07.

C08.9 is appropriate only when the specific gland cannot be determined from available documentation. Using secure oncology patient record systems that surface operative and pathology reports alongside billing data makes this distinction straightforward.

Reimbursement and insurance billing for malignant neoplasm of parotid gland

C07 is classified under head and neck malignancy DRG groups, which carry MCC and CC splits. Reimbursement varies by payer, provider type, and whether the claim is for an inpatient admission, outpatient surgical procedure, or evaluation and management (E&M) encounter.

Medicare and commercial payer considerations

Medicare covers parotid gland malignancy evaluation and treatment when medical necessity is supported by the documentation. The claim must include C07 as the primary diagnosis, with any required secondary codes. Pre-authorization requirements for surgical procedures (parotidectomy, neck dissection) vary by commercial payer. ENT and oncology practices should verify authorization requirements before scheduling surgery rather than relying on post-service appeals.

Complex staging or treatment-planning conversations that run long may also qualify for prolonged service billing, such as HCPCS code G2212, in addition to the standard E/M visit.

Practices using digital intake forms that capture relevant medical history at registration, including tobacco use, alcohol use, and prior head and neck radiation, give billing teams the secondary code data they need without chasing physicians for addenda. Pairing this with compliance management tools helps practices maintain audit-ready records across the full treatment episode.

Parotidectomy CPT codes that pair with C07

• CPT 42410: Parotidectomy, superficial, without facial nerve dissection
• CPT 42415: Parotidectomy, superficial, with facial nerve dissection
• CPT 42420: Parotidectomy, total, with facial nerve dissection (preserving the nerve)
• CPT 42425: Parotidectomy, total, with facial nerve sacrifice and neurotomy
• CPT 42440: Excision of submandibular gland (used when submandibular involvement is concurrent)

When billing parotidectomy procedures, C07 serves as the medical necessity diagnosis. Payers expect to see the CPT code paired with C07 as the diagnosis; a mismatch between the procedure and the diagnosis code is a common payer edit that triggers claim suspension.

Practices managing clinical documentation across the healthcare practice should build parotidectomy-specific templates that pre-populate the correct diagnosis code linkage.

Streamline oncology and ENT billing with Pabau

Pabau helps ENT and oncology practices capture the documentation required for accurate C07 claims, from intake forms that collect tobacco and alcohol history to structured clinical records that support staging and secondary code assignment. See how it works.

Book a demo

Skin and head and neck oncology practice workflow integration

ENT and head and neck oncology practices using skin and oncology clinic software can build C07-specific documentation workflows that standardize what the clinical note must include before billing. This reduces the back-and-forth between coders and physicians that often delays claim submission by days or weeks.

Key workflow integration points for parotid gland malignancy cases include structured note templates with required staging fields, automated pre-authorization triggers for surgical scheduling, and pathology report routing to both the clinical record and the billing queue simultaneously.

Conclusion

ICD-10 code C07 is a single billable code, but the billing complexity behind it is substantial. Most denials trace back to documentation: missing staging specificity, absent secondary codes for nodal disease, and premature assignment before pathology confirmation.

Getting C07 right means building a documentation workflow that captures these elements at every encounter, not a coding review after the fact.

Pabau’s structured client management and clinical record tools help ENT and oncology practices build note templates that surface staging, tobacco history, and lymph node status as required fields. To see how Pabau supports head and neck oncology documentation from first encounter through surveillance, book a demo.

Continue your research

Need a framework for documenting complex oncology encounters? Safer clinical notes covers structured note-writing principles for high-stakes clinical scenarios.

Want to catch claim denial patterns before they cost you revenue? Reporting and analytics surfaces denial trends across your practice so billing teams can fix root causes instead of chasing individual claims one at a time.

Want to standardize intake documentation for oncology patients? Capture Forms lets practices build structured intake templates that pre-populate tobacco and alcohol history fields.

Frequently Asked Questions